Insuman Comb 30 Solostar (Insulin Human (Rdna))

Insuman Comb 30 Solostar is a premixed insulin used to manage hyperglycemia in the diabetes therapeutic area.

• Type 1 diabetes mellitus: provides basal and prandial insulin coverage to achieve target glycemic control.
• Type 2 diabetes mellitus: supplements endogenous insulin to reduce fasting and post‑prandial glucose levels.
• Gestational diabetes: assists pregnant patients in maintaining safe maternal glucose concentrations.
• Diabetic ketoacidosis (adjunct): contributes to rapid glucose reduction when combined with intravenous insulin therapy.
• Insulin‑deficient states: supplies needed insulin in conditions of absolute insulin deficiency.

• Insulin human binds to insulin receptors on muscle, adipose and hepatic cells, activating the receptor’s tyrosine kinase activity. This triggers intracellular signaling cascades that promote glucose transporter (GLUT4) translocation, increase glucose uptake, and suppress hepatic gluconeogenesis, thereby lowering circulating blood glucose concentrations.

Adverse reactions may occur with any insulin therapy and should be monitored.

Common Side Effects

• Hypoglycemia: episodes of low blood glucose, especially if meals are missed or dosing is excessive.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Weight gain: modest increase due to improved glucose utilization.
• Lipodystrophy: localized changes in subcutaneous fat with repeated injections.
• Edema: mild peripheral swelling in some patients.

Serious or Rare Side Effects

• Severe hypoglycemia: can lead to loss of consciousness or seizures.
• Allergic reactions: including urticaria, angioedema, or anaphylaxis.
• Insulin antibodies: may alter insulin action and cause unpredictable glucose control.
• Lipohypertrophy: marked thickening of subcutaneous tissue affecting absorption.
• Hypokalemia: low potassium levels in rare cases of massive insulin administration.

When using Insuman Comb 30 Solostar, clinicians and patients should observe several safety measures.

• Blood glucose monitoring: check levels frequently to adjust dose and avoid hypoglycemia.
• Dose adjustment during illness: reduce or increase insulin as needed under medical guidance.
• Caution with renal impairment: impaired clearance may increase risk of prolonged hypoglycemia.
• Avoid use in active hypoglycemia: do not administer additional insulin until glucose is corrected.
• Concomitant beta‑blockers: may mask hypoglycemia symptoms, requiring closer observation.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Insuman Comb 30 Solostar may interact with several drug classes, influencing glucose control.

Major Interactions (Avoid)

• Sulfonylureas: additive hypoglycemic effect, increasing risk of severe low blood sugar.
• Beta‑blockers: can blunt typical hypoglycemia warning signs, complicating detection.
• Glucocorticoids: raise blood glucose, potentially requiring higher insulin doses.

Moderate Interactions (Monitor Closely)

• ACE inhibitors: may potentiate insulin’s glucose‑lowering effect, necessitating dose review.
• Thiazide diuretics: can cause modest hyperglycemia, requiring closer glucose monitoring.
• Oral contraceptives: may alter insulin sensitivity, warranting periodic dose assessment.